Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04525547) enrolled 70 participants, all of whom received the treatment being studied — a medication called Ofev (nintedanib). Of those 70 people, 65 completed the trial and 5 did not. The trial was measuring two main things: how many participants experienced adverse events (unwanted health events recorded during the study), and how a lung function measurement called Forced Vital Capacity (FVC) changed over time. FVC is simply a measure of how much air a person can forcefully breathe out in one go, recorded in millilitres (mL). The reported data shows that 36 out of 70 participants experienced at least one adverse event while taking Ofev. Regarding lung function, the reported data shows that the average FVC measurement changed by minus 15 mL after 12 weeks of treatment compared to where participants started — meaning, on average, the group's FVC was slightly lower than at the beginning. After 24 weeks, the reported average change was minus 44 mL compared to the starting point. The trial did not appear to include a comparison group (such as a placebo group), so these numbers reflect only the single group of participants who took Ofev. No secondary outcome measure data was reported in the structured results. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Interstitial Lung Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been prescribed and started on a medication called Ofev (nintedanib), following the approved guidelines for its use in Korea
- You have signed a form giving permission for your data to be used in the study
Who may not be able to join:
- You are not able to take nintedanib (Ofev) for medical reasons based on the official guidelines in Korea
- You have a known allergy or sensitivity to Ofev, peanuts, soya, or any of the ingredients in the medication
- You are currently pregnant or breastfeeding
- You have moderate or severe liver problems (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Patients With Adverse Events Who Took at Least One Dose of Ofev; Change From Baseline in Forced Vital Capacity) (FVC) (mL) After 12 Weeks of Treatment; Change From Baseline in Forced Vital Capacity) (FVC) (mL) After 24 Weeks of Treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.